2.07 USD
+0.14 (+7.25%)
2.12 USD
+0.05 (+2.42%)
Overall IPA gets a fundamental rating of 2 out of 10. We evaluated IPA against 58 industry peers in the Life Sciences Tools & Services industry. IPA may be in some trouble as it scores bad on both profitability and health. IPA is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
- In the past year IPA has reported negative net income.
- In the past year IPA has reported a negative cash flow from operations.
- IPA had negative earnings in each of the past 5 years.
- IPA had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- Looking at the Return On Assets, with a value of -68.03%, IPA is doing worse than 89.09% of the companies in the same industry.
- Looking at the Return On Equity, with a value of -127.97%, IPA is doing worse than 83.64% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -68.03% | ||
| ROE | -127.97% | ||
| ROIC | N/A |
ROA(3y)-49.16%
ROA(5y)-35.25%
ROE(3y)-84.68%
ROE(5y)-57.83%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Gross Margin of IPA (55.25%) is better than 65.45% of its industry peers.
- IPA's Gross Margin has been stable in the last couple of years.
- IPA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 55.25% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.87%
GM growth 5Y-0.67%
2. Health
2.1 Basic Checks
- IPA does not have a ROIC to compare to the WACC, probably because it is not profitable.
- Compared to 1 year ago, IPA has more shares outstanding
- The number of shares outstanding for IPA has been increased compared to 5 years ago.
- Compared to 1 year ago, IPA has a worse debt to assets ratio.
2.2 Solvency
- Based on the Altman-Z score of -0.35, we must say that IPA is in the distress zone and has some risk of bankruptcy.
- With a Altman-Z score value of -0.35, IPA is not doing good in the industry: 76.36% of the companies in the same industry are doing better.
- IPA has a Debt/Equity ratio of 0.49. This is a healthy value indicating a solid balance between debt and equity.
- IPA has a worse Debt to Equity ratio (0.49) than 63.64% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.49 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.35 |
ROIC/WACCN/A
WACC10.11%
2.3 Liquidity
- A Current Ratio of 2.08 indicates that IPA has no problem at all paying its short term obligations.
- Looking at the Current ratio, with a value of 2.08, IPA is in line with its industry, outperforming 43.64% of the companies in the same industry.
- A Quick Ratio of 1.85 indicates that IPA should not have too much problems paying its short term obligations.
- IPA has a Quick ratio (1.85) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.08 | ||
| Quick Ratio | 1.85 |
3. Growth
3.1 Past
- IPA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 34.78%, which is quite impressive.
- The Revenue has been growing slightly by 0.01% in the past year.
- Measured over the past years, IPA shows a quite strong growth in Revenue. The Revenue has been growing by 11.77% on average per year.
EPS 1Y (TTM)34.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%54.55%
Revenue 1Y (TTM)0.01%
Revenue growth 3Y8.19%
Revenue growth 5Y11.77%
Sales Q2Q%8.08%
3.2 Future
- The Earnings Per Share is expected to grow by 39.31% on average over the next years. This is a very strong growth
- The Revenue is expected to grow by 17.92% on average over the next years. This is quite good.
EPS Next Y49.5%
EPS Next 2Y48.39%
EPS Next 3Y35.81%
EPS Next 5Y39.31%
Revenue Next Year13.46%
Revenue Next 2Y22.45%
Revenue Next 3Y19.46%
Revenue Next 5Y17.92%
3.3 Evolution
- The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- IPA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IPA. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- IPA's earnings are expected to grow with 35.81% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y48.39%
EPS Next 3Y35.81%
5. Dividend
5.1 Amount
- No dividends for IPA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
IMMUNOPRECISE ANTIBODIES LTD / IPA FAQ
What is the ChartMill fundamental rating of IMMUNOPRECISE ANTIBODIES LTD (IPA) stock?
ChartMill assigns a fundamental rating of 2 / 10 to IPA.
What is the valuation status for IPA stock?
ChartMill assigns a valuation rating of 1 / 10 to IMMUNOPRECISE ANTIBODIES LTD (IPA). This can be considered as Overvalued.
Can you provide the profitability details for IMMUNOPRECISE ANTIBODIES LTD?
IMMUNOPRECISE ANTIBODIES LTD (IPA) has a profitability rating of 1 / 10.
What is the financial health of IMMUNOPRECISE ANTIBODIES LTD (IPA) stock?
The financial health rating of IMMUNOPRECISE ANTIBODIES LTD (IPA) is 2 / 10.